Ivosidenib is under clinical development by Les Laboratoires Servier and currently in Phase I for Low-Grade Glioma. According to GlobalData, Phase I drugs for Low-Grade Glioma have a 96% phase ...

Ivosidenib is under clinical development by Les Laboratoires Servier and currently in Phase III for Chondrosarcoma. According to GlobalData, Phase III drugs for Chondrosarcoma does not have sufficient ...

One or more of the following drugs will also be offered depending on the genetic profile of the tumour: futibatinib, ivosidenib, zanidatamab, trastuzumab, neratinib, encorafenib and binimetinib.

One or more of the following drugs will also be offered depending on the genetic profile of the tumour: futibatinib, ivosidenib, zanidatamab, trastuzumab, neratinib, encorafenib and binimetinib.

In the new study, patients diagnosed with the three main types of bile duct cancer (intrahepatic, perihilar or distal ...

The 2024 ELN risk stratification was developed with evidence from an exploratory analysis of pooled data from the phase 3 VIALE-A trial and a phase 1 b study of azacitidine plus venetoclax. The ...

Across patients with high-risk disease, median OS was significantly improved for the 4 patients who received an IDH1 inhibitor, either ivosidenib or olutasidenib, compared with the 28 patients who ...

We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...